Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ChemGenex Pharmaceuticals has signed a new three year alliance agreement with its long-term pharmaceutical industry partner Merck KGaA to provide preclinical support in the fields of diabetes, insulin resistance and complications.
Subscribe to our email newsletter
Under the terms of the agreement, which is valid until the end of 2008, ChemGenex will receive a total retainer fee of approximately A$1 million, with potential additional payments depending on the amount and type of preclinical support provided.
The new agreement follows the successful completion of three research contracts in target discovery, and reflects a strong ongoing relationship between Merck KGaA and ChemGenex.
“This new agreement is a strong endorsement by Merck of the value they see in ChemGenex’s diabetes expertise, and of our strong competitive position in this field,” said Dr Greg Collier, CEO of ChemGenex.
ChemGenex develops therapeutics in the areas of oncology, diabetes, obesity, and depression.